SARS-Cov-2 vaccine's acceptance among pregnant women-A cross-sectional survey
Copyright © 2022 Elsevier Masson SAS. All rights reserved..
OBJECTIVE: SARS-CoV-2 is more likely to cause severe cases in pregnant women. They were part of the priority groups since April 2021 to benefit from SARS-CoV-2 vaccination before its extent to general population. This contribution aims to evaluate, in the postpartum period, the achievement of COVID-19 vaccination and factors associated in women during their pregnancy.
MATERIAL AND METHOD: Multicenter cross-sectional survey study conducted from September to December 2021 with online self-questionnaire. All postpartum patients hospitalized in one of the 6 participating maternity hospitals were invited to answer. The questionnaire asked patients about their demographic characteristics, vaccination modalities, vaccine tolerance, and their general perception of vaccination.
RESULTS: Of the 371 women who responded, the vaccination rate was 65.7% (IC95% [60.8-70.4]), whom 98.8% entirely during pregnancy. Associated factors with vaccination during pregnancy were older age, higher socio-professional category, and prior information provided by health professionals. Factors that appear to motivate vaccination were personal protection and protection of the newborn. Finally, main factors negatively influencing the vaccination process were the fear of vaccine side effects and the negative perception of vaccines in general.
DISCUSSION: Acceptability and information about the vaccine by health professionals is in constant improvement. Information campaigns should be continued to improve the acceptability of vaccination, in light of the accumulating data.
| Errataetall: |
CommentIn: Gynecol Obstet Fertil Senol. 2022 Nov;50(11):748. - PMID 36155107 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Gynecologie, obstetrique, fertilite & senologie - 50(2022), 11 vom: 04. Nov., Seite 712-720 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Acceptabilité du vaccin-Sars CoV-2 chez les femmes enceintes, une enquête transversale par questionnaire |
|---|
| Beteiligte Personen: |
Huré, M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 Vaccines |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 01.11.2023 published: Print-Electronic CommentIn: Gynecol Obstet Fertil Senol. 2022 Nov;50(11):748. - PMID 36155107 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.gofs.2022.07.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344343677 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344343677 | ||
| 003 | DE-627 | ||
| 005 | 20231226022541.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.gofs.2022.07.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1147.xml |
| 035 | |a (DE-627)NLM344343677 | ||
| 035 | |a (NLM)35914734 | ||
| 035 | |a (PII)S2468-7189(22)00236-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Huré, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-Cov-2 vaccine's acceptance among pregnant women-A cross-sectional survey |
| 246 | 3 | 3 | |a Acceptabilité du vaccin-Sars CoV-2 chez les femmes enceintes, une enquête transversale par questionnaire |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 01.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Gynecol Obstet Fertil Senol. 2022 Nov;50(11):748. - PMID 36155107 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a OBJECTIVE: SARS-CoV-2 is more likely to cause severe cases in pregnant women. They were part of the priority groups since April 2021 to benefit from SARS-CoV-2 vaccination before its extent to general population. This contribution aims to evaluate, in the postpartum period, the achievement of COVID-19 vaccination and factors associated in women during their pregnancy | ||
| 520 | |a MATERIAL AND METHOD: Multicenter cross-sectional survey study conducted from September to December 2021 with online self-questionnaire. All postpartum patients hospitalized in one of the 6 participating maternity hospitals were invited to answer. The questionnaire asked patients about their demographic characteristics, vaccination modalities, vaccine tolerance, and their general perception of vaccination | ||
| 520 | |a RESULTS: Of the 371 women who responded, the vaccination rate was 65.7% (IC95% [60.8-70.4]), whom 98.8% entirely during pregnancy. Associated factors with vaccination during pregnancy were older age, higher socio-professional category, and prior information provided by health professionals. Factors that appear to motivate vaccination were personal protection and protection of the newborn. Finally, main factors negatively influencing the vaccination process were the fear of vaccine side effects and the negative perception of vaccines in general | ||
| 520 | |a DISCUSSION: Acceptability and information about the vaccine by health professionals is in constant improvement. Information campaigns should be continued to improve the acceptability of vaccination, in light of the accumulating data | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Grossesse | |
| 650 | 4 | |a Pregnancy | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a SARS-Cov-2 | |
| 650 | 4 | |a Vaccin | |
| 650 | 4 | |a Vaccine | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Peyronnet, V |e verfasserin |4 aut | |
| 700 | 1 | |a Sibiude, J |e verfasserin |4 aut | |
| 700 | 1 | |a Cazenave, M G |e verfasserin |4 aut | |
| 700 | 1 | |a Anselem, O |e verfasserin |4 aut | |
| 700 | 1 | |a Luton, D |e verfasserin |4 aut | |
| 700 | 1 | |a Vauloup-Fellous, C |e verfasserin |4 aut | |
| 700 | 1 | |a Deruelle, P |e verfasserin |4 aut | |
| 700 | 1 | |a Cordier, A G |e verfasserin |4 aut | |
| 700 | 1 | |a Benachi, A |e verfasserin |4 aut | |
| 700 | 1 | |a Mandelbrot, L |e verfasserin |4 aut | |
| 700 | 1 | |a Couffignal, C |e verfasserin |4 aut | |
| 700 | 1 | |a Pauphilet, V |e verfasserin |4 aut | |
| 700 | 1 | |a Vivanti, A J |e verfasserin |4 aut | |
| 700 | 1 | |a Picone, O |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gynecologie, obstetrique, fertilite & senologie |d 2017 |g 50(2022), 11 vom: 04. Nov., Seite 712-720 |w (DE-627)NLM269302743 |x 2468-7189 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2022 |g number:11 |g day:04 |g month:11 |g pages:712-720 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.gofs.2022.07.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2022 |e 11 |b 04 |c 11 |h 712-720 | ||